Company Filing History:
1 out of 137 
1 out of 70 
1 out of 113 
Years Active: 2024
Title: Mikio Okazaki: Innovator in Cancer Research
Introduction
Mikio Okazaki is a prominent inventor based in Okayama, Japan. He has made significant contributions to the field of cancer research through his innovative work on antibodies. His research focuses on developing effective treatments for cancer metastasis and inflammatory diseases.
Latest Patents
Mikio Okazaki holds a patent for an "Anti-S100A8/A9 antibody and use thereof." This invention provides a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that acts on inflammatory diseases. The pharmaceutical composition contains an antibody or an antibody fragment that has antigen-binding activity for the S100A8/A9 heterodimer. This invention blocks the interaction between S100A8/A9 and its receptors, thereby strongly suppressing cancer metastasis both in vitro and in vivo, or alleviating inflammation. The anti-S100A8/A9 antibody can significantly impact cancer treatment and inflammatory conditions.
Career Highlights
Mikio Okazaki has worked at notable institutions, including Okayama University and Niigata University. His research has been instrumental in advancing the understanding of cancer biology and therapeutic interventions. His dedication to scientific inquiry has led to valuable insights and innovations in the medical field.
Collaborations
Mikio Okazaki has collaborated with esteemed colleagues, including Masakiyo Sakaguchi and Shinichi Toyooka. These partnerships have fostered a collaborative environment that enhances research outcomes and drives innovation.
Conclusion
Mikio Okazaki's contributions to cancer research through his patented inventions highlight his role as a leading inventor in the field. His work not only advances scientific knowledge but also holds the potential for significant therapeutic applications.